ClinicalTrials.gg
CompletedNCT03823391Updated Jul 19, 2021Results posted

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

A Phase 2 interventional study of ABBV-3373 and Placebo for ABBV-3373 in Rheumatoid Arthritis (RA), sponsored by AbbVie. Completed at 30 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-19.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
71st of 87
48 · median 160
Started
2019
with 3 others
Phase 2
9 of 87
2 open now
Registered
78th of 87
by date
Lead sponsor
5 of 87
AbbVie

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 71st largest by enrollment, is one of 4 that started in 2019, is one of 9 in phase 2, and was the 78th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.

Read the detailed description

This study consists of a 12-week double-blind active-controlled phase and a 12 week double-blind extension period.

In the active-controlled period of the first 12 weeks of treatment, participants are randomized to receive either ABBV-3373 100 mg intravenously (IV) every other week (EOW) or adalimumab 80 mg subcutaneously (SC) EOW according to a 2:1 ratio.

At Week 12, the administration of ABBV-3373 was to stop to assess the durability of the observed clinical effects up to 24 weeks. Participants randomized to ABBV-3373 were to receive placebo injections, whereas participants randomized into the adalimumab arm were to continue their 80 mg dosing.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Rheumatoid Arthritis (RA)
  • ABBV-3373
  • Adalimumab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has the clinical diagnosis of RA for > 3 months based on the 1987 American College of Rheumatology (ACR) classification criteria or 2010 ACR/European League against Rheumatism (EULAR) criteria.
  • Participant meets the following disease activity criteria: >= 4 swollen joints (based on 28 joint count) and >= 4 tender joints (based on 28 joint count) at Screening and Baseline visits and disease activity score (28 joints) (DAS28) C-reactive protein (CRP) >= 3.2 at Screening.
  • Participant has an incomplete response to methotrexate. Participants must have been on oral or parental MTX therapy >= 3 months and on a stable prescription of 15 to 25 mg/week (or >= 10 mg/week in participants intolerant of MTX at doses >= 15 mg/week) for >= 4 weeks prior to the first dose of study drug. Participant must be expected to be able to continue on stable dose of MTX for the duration of study participation.

Exclusion criteria

Exclusion Criteria:

  • Participants previously exposed to adalimumab or other anti-tumor necrosis factor (TNF) biologics.
  • Participants previously exposed to non-anti-TNF biologics or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for RA, with exception of participants exposed for less than 3 months and terminated not due to lack of efficacy or intolerability.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    ABBV-3373 Followed by Placebo

    Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.

    Drug: ABBV-3373 · Drug: Placebo for adalimumab

  • Experimental
    Adalimumab

    Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.

    Drug: Placebo for ABBV-3373 · Drug: Adalimumab

Interventions

  • DrugABBV-3373

    ABBV-3373 is administered as intravenous (IV) infusion

  • DrugPlacebo for ABBV-3373

    Placebo for ABBV-3373 is administered as IV infusion

  • Adalimumab is administered as subcutaneous (SC) injection

    Also known as: Humira

  • DrugPlacebo for adalimumab

    Placebo for adalimumab is administered as subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP])

    The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a visual analog scale \[VAS\] from 0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 (CRP) range from 0.96 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in Clinical Disease Activity Index (CDAI)

    The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of tender joint count (out of 28 evaluated joints) and swollen joint count (out of 28 evaluated joints), Patient Global Assessment of Disease Activity and Physician Global Assessment of Disease Activity both measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Simplified Disease Activity Index (SDAI)

    The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), Patient Global Assessment of Disease Activity and Physician Global Assessment of Disease Activity both measured on a VAS from 0-10 cm and level of CRP (in mg/dL; normal \< 1 mg/dL). The SDAI has a range from 0 to 86, with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.

    Time frame: Baseline and Week 12

  3. Change From Baseline to Week 12 in DAS28 (Erythrocyte Sedimentation Rate [ESR])

    The DAS28 (ESR) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a VAS from 0-100 mm), and ESR (in mm/hr). Scores on the DAS28 (ESR) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.

    Time frame: Baseline and Week 12

  4. Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12

    The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a VAS from 0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 (CRP) range from 0.96 to approximately 10, where higher scores indicate more disease activity. A DAS28 (CRP) score less than or equal to 3.2 indicates low disease activity.

    Time frame: Week 12

  5. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

07

Results

Posted Jul 19, 2021

Participant flow

Participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) were enrolled at 14 sites in the United States and Puerto Rico, Poland, Hungary, and Israel.

Period 1: Week 1 to Week 12
Participant flow — Period 1: Week 1 to Week 12
MilestoneAdalimumabABBV-3373 Followed by Placebo
Started1731
Completed1731
Not completed00
Period 2: Weeks 12 to Week 24
Participant flow — Period 2: Weeks 12 to Week 24
MilestoneAdalimumabABBV-3373 Followed by Placebo
Started1731
Completed1530
Not completed21
Withdrew: Adverse event11
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryChange From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP])

The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a visual analog scale \[VAS\] from 0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 (CRP) range from 0.96 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP])
score on a scaleAdalimumabABBV-3373
Change From Baseline to Week 12 in Disease Activity Score (DAS) 28 (C-reactive Protein [CRP])-2.51 ± 0.293-2.65 ± 0.215
Statistical analysis
  • ABBV-3373 · Mixed-effect model repeated measurement · p = 0.022 · Least squares (ls) mean difference: -0.52 · 90% CI -0.89 to -0.15Between groups difference was a single-arm comparison of LS mean of ABBV-3373 estimated from the MMRM model above minus the historical mean of adalimumab (-2.13).
  • ABBV-3373 · Historical data borrowing · p = 0.899 (Posterior probability)Based on posterior distribution of means for each group, the probability of Treatment mean - Control mean \< 0 given the observed data was calculated.
  • Adalimumab vs ABBV-3373 · Mixed Effect Model Repeated Measurement · p = 0.683 · Ls mean difference: -0.15 · 90% CI -0.74 to 0.45Treatment difference = ABBV-3373 - Adalimumab
SecondaryChange From Baseline to Week 12 in Clinical Disease Activity Index (CDAI)

The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of tender joint count (out of 28 evaluated joints) and swollen joint count (out of 28 evaluated joints), Patient Global Assessment of Disease Activity and Physician Global Assessment of Disease Activity both measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Clinical Disease Activity Index (CDAI)
score on a scaleAdalimumabABBV-3373
Change From Baseline to Week 12 in Clinical Disease Activity Index (CDAI)-26.30 ± 2.656-27.99 ± 1.955
Statistical analysis
  • Adalimumab vs ABBV-3373 · Mixed Effect Model Repeated Measurement · p = 0.601 · Ls mean difference: -1.69 · 90% CI -7.08 to 3.70Treatment difference = ABBV-3373 - Adalimumab
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI)

The SDAI is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), Patient Global Assessment of Disease Activity and Physician Global Assessment of Disease Activity both measured on a VAS from 0-10 cm and level of CRP (in mg/dL; normal \< 1 mg/dL). The SDAI has a range from 0 to 86, with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI)
score on a scaleAdalimumabABBV-3373
Change From Baseline in Simplified Disease Activity Index (SDAI)-27.42 ± 2.659-28.50 ± 1.961
Statistical analysis
  • Adalimumab vs ABBV-3373 · Mixed Effect Model Repeated Measurement · p = 0.737 · Ls mean difference: -1.08 · 90% CI -6.47 to 4.30Treatment difference = ABBV-3373 - Adalimumab
SecondaryChange From Baseline to Week 12 in DAS28 (Erythrocyte Sedimentation Rate [ESR])

The DAS28 (ESR) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a VAS from 0-100 mm), and ESR (in mm/hr). Scores on the DAS28 (ESR) range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in DAS28 (Erythrocyte Sedimentation Rate [ESR])
score on a scaleAdalimumabABBV-3373
Change From Baseline to Week 12 in DAS28 (Erythrocyte Sedimentation Rate [ESR])-2.55 ± 0.344-2.76 ± 0.254
Statistical analysis
  • Adalimumab vs ABBV-3373 · Mixed Effect Model Repeated Measurement · p = 0.612 · Ls mean difference: -0.21 · 90% CI -0.92 to 0.49Treatment difference = ABBV-3373 - Adalimumab
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12

The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (measured on a VAS from 0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 (CRP) range from 0.96 to approximately 10, where higher scores indicate more disease activity. A DAS28 (CRP) score less than or equal to 3.2 indicates low disease activity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12
percentage of participantsAdalimumabABBV-3373
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 1258.8 (39.2 to 78.5)54.8 (40.1 to 69.5)
Statistical analysis
  • Adalimumab vs ABBV-3373 · Cochran-Mantel-Haenszel · p = 0.877 · Response rate difference: -4.0 · 90% CI -28.5 to 20.5Response rate difference = ABBV-3373 - Adalimumab
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
percentage of participantsAdalimumabABBV-3373
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 1264.7 (45.6 to 83.8)51.6 (36.8 to 66.4)
Statistical analysis
  • Adalimumab vs ABBV-3373 · Cochran-Mantel-Haenszel · p = 0.426 · Response rate difference: -13.1 · 90% CI -37.2 to 11.0Response rate difference = ABBV-3373 - Adalimumab

Adverse events

Collected over From first dose of study drug up to 70 days after last dose; the treatment duration was 12 weeks in each period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: ABBV-33730/31 (0%)4/31 (12.9%)4/31 (12.9%)
Period 1: Adalimumab0/17 (0%)0/17 (0%)12/17 (70.6%)
Period 2: ABBV-3773 / Placebo0/30 (0%)0/30 (0%)7/30 (23.3%)
Period 2: Adalimumab / Adalimumab0/16 (0%)2/16 (12.5%)12/16 (75%)
Most frequent serious events
Most frequent serious events
EventPeriod 1: ABBV-3373Period 1: AdalimumabPeriod 2: ABBV-3773 / PlaceboPeriod 2: Adalimumab / Adalimumab
BREAST ABSCESSInfections and infestations0/310/170/301/16
BRONCHITISInfections and infestations0/310/170/301/16
NON-CARDIAC CHEST PAINGeneral disorders1/310/170/300/16
ANAPHYLACTIC SHOCKImmune system disorders1/310/170/300/16
PNEUMONIAInfections and infestations1/310/170/300/16
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/310/170/300/16
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPeriod 1: ABBV-3373Period 1: AdalimumabPeriod 2: ABBV-3773 / PlaceboPeriod 2: Adalimumab / Adalimumab
NASOPHARYNGITISInfections and infestations0/311/173/302/16
URINARY TRACT INFECTIONInfections and infestations2/312/171/301/16
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders0/310/173/300/16
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/310/172/301/16
HEADACHENervous system disorders2/311/170/301/16
LEUKOPENIABlood and lymphatic system disorders0/310/170/301/16
PERIORBITAL SWELLINGEye disorders0/310/170/301/16
MOUTH SWELLINGGastrointestinal disorders0/310/170/301/16
NAUSEAGastrointestinal disorders0/310/170/301/16
INJECTION SITE PRURITUSGeneral disorders0/310/170/301/16

Baseline characteristics

The Full Analysis Set (FAS) includes all randomized participants who received at least 1 dose of the study drugs.

Age, Continuous
Age, Continuous(years)AdalimumabABBV-3373 Followed by PlaceboTotal
Mean54.0 ± 10.2152.8 ± 13.1453.2 ± 12.08
Age, Customized
Age, Customized(Participants)AdalimumabABBV-3373 Followed by PlaceboTotal
< 40 years055
40 to 65 years132134
≥ 65 years459
Sex: Female, Male
Sex: Female, Male(Participants)AdalimumabABBV-3373 Followed by PlaceboTotal
Female142438
Male3710
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AdalimumabABBV-3373 Followed by PlaceboTotal
Hispanic or Latino3811
Not Hispanic or Latino142337
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AdalimumabABBV-3373 Followed by PlaceboTotal
White162844
Black123
Other011
Duration of RA Symptoms
Duration of RA Symptoms(years)AdalimumabABBV-3373 Followed by PlaceboTotal
Mean5.9 ± 3.228.0 ± 8.737.2 ± 7.29
Duration of RA Diagnosis
Duration of RA Diagnosis(years)AdalimumabABBV-3373 Followed by PlaceboTotal
Mean3.5 ± 3.095.0 ± 6.024.5 ± 5.19
Baseline Use of Systemic Glucocorticoids
Baseline Use of Systemic Glucocorticoids(Participants)AdalimumabABBV-3373 Followed by PlaceboTotal
Yes51116
No122032

2 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Rheum Assoc of North Alabama /ID# 213626
    Huntsville, Alabama 35801, United States
  • AZ Arthritis and Rheum Researc /ID# 208515
    Phoenix, Arizona 85032, United States
  • C.V. Mehta MD, Med Corporation /ID# 213068
    Hemet, California 92543, United States
  • Robin K. Dore MD, Inc /ID# 213045
    Tustin, California 92780, United States
  • Inland Rheum & Osteo Med Grp /ID# 213044
    Upland, California 91786, United States
  • Suncoast Clinical Research /ID# 213973
    New Port Richey, Florida 34652, United States
  • Arthritis Center, Inc. /ID# 213972
    Palm Harbor, Florida 34684, United States
  • W. Broward Rheum Assoc Inc. /ID# 211017
    Tamarac, Florida 33321, United States
  • BayCare Medical Group, Inc. /ID# 213935
    Tampa, Florida 33614-7101, United States
  • Institute of Arthritis Researc /ID# 213043
    Idaho Falls, Idaho 83404, United States
  • PRN Professional Research Network of Kansas, LLC /ID# 213046
    Wichita, Kansas 67205, United States
  • Clinvest Research LLC /ID# 215451
    Springfield, Missouri 65810-2607, United States
  • Duke Early Phase Research Unit (DCRI) /ID# 213212
    Durham, North Carolina 27710, United States
  • Paramount Medical Research Con /ID# 209042
    Middleburg Heights, Ohio 44130, United States
  • STAT Research, Inc. /ID# 213933
    Vandalia, Ohio 45377-9464, United States
  • West Tennessee Research Inst /ID# 208838
    Jackson, Tennessee 38305, United States
  • PCCR Solution /ID# 215457
    Colleyville, Texas 76034, United States
  • Trinity Universal Research Association /ID# 209167
    Plano, Texas 75024-5283, United States
  • Charite Research Organisation GmbH /ID# 210216
    Berlin, 10117, Germany
  • CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 210055
    Miskolc, Borsod-Abauj-Zemplen 3529, Hungary
  • DRC Gyogyszervizsgalo Kozpont Kft. /ID# 210159
    Balatonfüred, Veszprem 8230, Hungary
  • Budai Irgalmasrendi Korhaz /ID# 208877
    Budapest, 1023, Hungary
  • Debreceni Egyetem Klinikai Kozpont /ID# 210164
    Debrecen, 4032, Hungary
  • Rambam Health Care Campus /ID# 212747
    Haifa, 3109601, Israel
  • Sheba Medical Center /ID# 211339
    Ramat Gan, 5239424, Israel
  • Academisch Medical center Amsterdam /ID# 209303
    Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • SANUS Szpital Specjalistyczny /ID# 209022
    Stalowa Wola, 37-450, Poland
  • Reumatika - Centrum Reumatologii NZOZ /ID# 209220
    Warsaw, 02-691, Poland
  • GCM Medical Group, PSC /ID# 208154
    San Juan, 00909, Puerto Rico
  • Mindful Medical Research /ID# 208403
    San Juan, 00918-3756, Puerto Rico
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Apr 2020, 12 months.

Results were first posted in Jul 2021, 1 year 3 months after primary completion. A results delay was requested in Mar 2021.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 12 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Jan 30, 2019
StartActual
Mar 27, 2019
Primary completionActual
Apr 8, 2020
CompletionActual
Aug 26, 2020
Results delay requested
Mar 23, 2021
Results first posted
Jul 19, 2021
Last update
Jul 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03823391
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Mar 27, 2019
Primary completion
Apr 8, 2020
Completion
Aug 26, 2020
Results posted
Jul 19, 2021
Last update
Jul 19, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion